诺瓦瓦克斯医药涨超20%

Core Viewpoint - Novavax Pharmaceuticals' stock surged over 20% following the announcement that its COVID-19 vaccine has received approval [1] Group 1 - The approval of the COVID-19 vaccine is a significant milestone for Novavax, potentially enhancing its market position and revenue prospects [1] - The stock price increase reflects positive investor sentiment and confidence in the company's future performance [1]